Peptides Codex
ENFR
← Home
GnRH antagonist (decapeptide analog)

Teverelix

Teverelix is a synthetic decapeptide GnRH antagonist that binds competitively and reversibly to pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone. It is an investigational compound studied in prostate disorders and is not authorized by Health Canada. This page is educational and is not medical advice.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
10 aa
Class
GnRH antagonist (decapeptide analog)
Function
Competitive gonadotropin-releasing hormone receptor antagonist
Context
Investigational GnRH antagonist studied for prostate cancer and benign prostatic conditions; not authorized by Health Canada

A clinical-stage GnRH antagonist studied as an alternative to established agents.

Also known as: teverelix TFA · GnRH antagonist

Part of the Foundational & therapeutic peptides cluster

Overview

Teverelix is a synthetic decapeptide GnRH antagonist that binds competitively and reversibly to pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone. It is an investigational compound studied in prostate disorders and is not authorized by Health Canada. This page is educational and is not medical advice.

Source & context

Biological / chemical source: Synthetic decapeptide analog of GnRH

Primary research or clinical context: Investigational GnRH antagonist studied for prostate cancer and benign prostatic conditions; not authorized by Health Canada

Where it sits in the class

Teverelix belongs to the same peptide-antagonist family as cetrorelix, ganirelix, abarelix, and degarelix. Research interest centers on formulation and pharmacokinetics that could offer practical advantages, but its status remains investigational.

Mechanism

By competitively blocking the GnRH receptor, teverelix suppresses gonadotropins without the initial hormone flare characteristic of agonists. Reported clinical studies have evaluated its pharmacokinetics, safety, and hormone-suppressing effects.

FAQ about Teverelix

What is Teverelix?+

Teverelix is a synthetic decapeptide GnRH antagonist that binds competitively and reversibly to pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone. It is an investigational compound studied in prostate disorders and is not authorized by Health Canada. This page is educational and is not medical advice.

Is Teverelix an approved medicine?+

Teverelix is discussed here as a research / educational topic. Investigational GnRH antagonist studied for prostate cancer and benign prostatic conditions; not authorized by Health Canada. This is not medical advice.

What is the typical length of Teverelix?+

Teverelix is commonly described as approximately 10 amino acids (GnRH antagonist (decapeptide analog)).

Related peptides

PE-22-28
Research peptide
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Cortexin
Polypeptide complex
Cortexin is a low-molecular-weight polypeptide complex extracted from cerebral cortex tissue, studied largely in Russian neuroscience literature. It is marketed as a drug in some countries but is not authorized by Health Canada.
Pinealon
Research peptide
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, EDR) from the Khavinson short-peptide bioregulator class. It has been studied for proposed neuroprotective and gene-regulatory effects in mostly Russian laboratory research and is not authorized as a medicine by Health Canada.
Cetrorelix
GnRH antagonist (decapeptide analog)
Cetrorelix is a synthetic decapeptide GnRH antagonist that competitively blocks the GnRH receptor. It is an approved prescription medicine used in in-vitro fertilization to prevent premature luteinizing hormone surges. This page is educational and is not medical advice.

References & further reading

  1. 1.PubChem — compound summary for Teverelix (CID 16135076)
  2. 2.PubMed — Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate (PMID 34448368)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Teverelix educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.